However, agents targeting the Bcl-2 protein family have been generally shown to be a potent killer of tumor cells derived from hematologic malignancies and accumulating evidence supports the idea that the treatment of other cancer entities may strongly benefit from the Bcl-2-antagonizing protocols in combination with other chemotherapy regimens. Here, BCL2 is linked to hematologic disorder.